Eunice Bakr
0
All posts from Eunice Bakr
Eunice Bakr in Eunice Bakr,

Amgen reports success of Phase 3 clinical trial, stocks up 1.35%

Amgen and its subsidiary, Onyx Pharmaceuticals today announced that a planned interim analysis demonstrated that the Phase 3 clinical trial ASPIRE (CArfilzomib, Lenalidomide, and DexamethaSone versus Lenalidomide and Dexamethasone for the treatment of PatIents with Relapsed Multiple MyEloma) met its primary endpoint of progression-free survival (PFS). Patients treated with Kyprolis®(carfilzomib) for Injection in combination with Revlimid®(lenalidomide) and low-dose dexamethasone (KRd) lived significantly longer without their disease worsening (median 26.3 months) compared to patients treated with Revlimid and low-dose dexamethasone (Rd) (median 17.6 months) (HR=0.690, 95 percent CI, 0.570, 0.834, p<0.0001).

Source: MarketWatch

Amgen added 1.35% on Nasdaq today